The clinical development program being executed through Suven Neurosciences, Inc., a Delaware Company in USA, a whole owned subsidiary of Suven Life Sciences. Suven Life Sciences, a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening Central Nervous System(CNS) disorders, declared dose administration of in a very section 2A trial of SUVN G-3031, an amine H3 receptor inverse agonist in a very double-b....
Tags : SUVN G-3031, amine H3, SUVN-G3031, Central Nervous System(CNS) disorders, Suven Life Sciences, Suven Neurosciences, Inc., CNS Disorders, materia medica (PK),
comments (0)